Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-18
SponsorGazi University

About this trial

Primary immunodeficiencies (PID) are a heterogeneous group of diseases that occur as a result of disorders that affect the development, differentiation and/or function of various cells and building blocks in the immune system. Among the symptoms and complications of PID, pulmonary complications are very common and significantly increase the morbidity and mortality of the disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Acute pulmonary exacerbation, acute upper or lower respiratory tract infection

Serious neurological, neuromuscular, orthopedic and other systemic diseases or other diseases affecting physical functions

Participating in a planned exercise program in the past three months

Cognitive impairment, which may cause difficulty understanding and following exercise test instructions

Trial design

Design model

Parallel

Treatments tested in this trial

  • Inspiratory muscle training

    Other intervention

    Inspiratory muscle training will be performed with Power Breathe®. Inspiratory muscle training will be given to the training group, starting from 50% of the MIP, and 2 sessions/day, 15 minutes/session. Patients will be asked to check breathing for 4-5 breaths after 8-10 consecutive breathing cycles. The patient will continue this cycle for 15 minutes.

  • Upper extremity aerobic exercise training

    Other intervention

    Upper extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 min/session using arm ergometer device accompanied by a physiotherapist. Aerobic exercise training workload will be 60-80% of maximal heart rate. In this study, the perception of dyspnea will be between 3-4, arm fatigue and general fatigue perception will be between 5-6, warm-up and cool-down periods will be 5 minutes, and pedaling speed will be 40-50 rev/min, according to MBS.

  • Lower extremity aerobic exercise training

    Other intervention

    Lower extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 minutes/session using the treadmill device, accompanied by a physiotherapist. Aerobic exercise training workload was set at 60-80% of maximal heart rate, dyspnea perception according to MBS was between 3-4, arm fatigue and general fatigue perception was between 5-6, and warm-up and cool-down periods were 5 minutes.

  • Resistant exercise training

    Other intervention

    Upper and lower additional limb strengthening training will be performed 3 days/week, 1 session/day, 10 repetitions/sessions from the first day by using bullion weights in the presence of a physiotherapist. The upper extremity strengthening program will consist of a progressive exercise program to strengthen the shoulder flexors and abductors, and the lower extremity strengthening program to strengthen the knee extensors. The training workload will be increased progressively. For strength training, the workload will be adjusted so that the perception of fatigue is between 4 and 6 according to MBS.

  • Thoracic expansion exercises

    Other intervention

    The control group will be asked to do thoracic expansion exercises seven days/week and 120 pieces/day for six weeks.

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Pulmonary Rehabilitation GroupExperimental treatment 4 interventions
Group B: Control GroupSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Oxygen Consumption

Cardiopulmonary Exercises Test

Time frame
First Day

Secondary outcomes

1

Pulmonary function (Forced vital capacity (FVC))

Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. With the device, forced vital capacity (FVC) will be evaluated.

Time frame
Second Day
2

Pulmonary function (Forced expiratory volume in the first second (FEV1))

Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to ATS and ERS criteria. With the device, forced expiratory volume in the first second (FEV1) will be evaluated.

Time frame
Second Day
3

Pulmonary function (FEV1 / FVC)

Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to ATS and ERS criteria. With the device, FEV1 / FVC will be evaluated.

Time frame
Second Day
4

Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%))

Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to ATS and ERS criteria. With the device, flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be evaluated.

Time frame
Second Day

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.